Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-25

Study Completion Date

2021-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Long-Term Safety Study of OZURDEX® in Clinical Practice

NCT01539577

Retinal Vein Occlusion Macular Edema Uveitis, Posterior

COMPLETED

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

NCT01870440

Macular Edema Uveitis

COMPLETED PHASE4

Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

NCT05697809

Diabetic Macular Edema

COMPLETED PHASE2

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

NCT01566526

Retinal Vein Occlusion Macular Oedema

COMPLETED

Anatomic Outcomes Following Ozurdex Injections

NCT01282411

Retinal Vein Occlusions

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Eye

OZURDEX implant 700 μg

Group Type EXPERIMENTAL

OZURDEX

Intervention Type DRUG

Implant 700 μg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OZURDEX

Implant 700 μg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic)
* Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit
* BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening
* \< 3 months of macular edema duration
* Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO)

Exclusion Criteria

* Uncontrolled systemic disease
* Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment)
* Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months:
* Intraocular surgery
* Laser photocoagulation
* Intraocular injection
* Periocular steroid injection
* Vitrectomized eye
* Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens
* History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a \>10 mm Hg increase in IOP from predose, or (c) resulted in IOP \>25 mm Hg
* History of glaucoma or ocular hypertension (IOP \> 21 mm Hg), or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye (patients with a history of previous angle closure that has been successfully treated with either a laser or surgical peripheral iridotomy \[PI\] are allowed as long as the visual fields have been stable for \> 1 year prior to study entry and the patient has been and can be safely dilated).
* Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening visit
* Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception
* Any condition that may interfere or preclude participation in the study
* Use of systemic steroids (e.g., oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to Baseline or anticipated use at any time during the study (inhaled, intranasal, and intra-articular/intrabursal corticosteroids are allowed)
* Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to Baseline or anticipated use at any time during the study
* Use of warfarin or heparin within 2 weeks prior to Baseline or anticipated use within the study period
* Known allergy, hypersensitivity or contraindication to the study medication, its components, fluorescein or povidone iodine
* Current enrollment in another drug or device study within 30 days prior to Baseline

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No